Association of p53 Accumulation With TP53 Mutations, Loss of Heterozygosity at 17p13, and DNA Ploidy Status in 273 Colorectal Carcinomas.F. Clausen Ole Petter M.D. Ph.D.; Lothe, Ragnhild A. Ph.D.; Børresen-Dale, Anne-Lisc Ph.D.; Angelis, Paula De Ph.D.; Chen, Ying M.D.; Rognum, Torleiv O. M.D., Ph.D.; Meling, Gunn Iren M.D., Ph.D.Diagnostic Molecular Pathology: August 1998 Original Articles: PDF Only Buy Abstract The aim of this study was to establish an experimentally based cutoff level for assessing p53 immunoreactivity in colorectal tumors. The accumulation of p53 protein in 273 colorectal tumors was correlated with previously obtained data on TP53 mutation and loss of heterozygosity at two 17p13 loci in the same tumors. The monoclonal antibody PAb 1801 was used for p53 staining, and the results obtained by immunohistochemistry and immunoblotting were similar. Mutation analyses of exons 5-8 were performed using constant denaturant gel electrophoresis followed by sequencing. There were no statistically significant differences for any measured TP53 gene alteration between the group of tumors without p53-positive nuclei (n = 83) and the group with <5% positive nuclei (n = 58). The majority of mutations within these groups were deletions/insertions and nonsense mutations without p53 accumulation. Therefore, we assume that 5% p53-positive nuclei is the relevant cutoff level to assess TP53 damage in colorectal tumors. A prerequisite for this recommendation is optimal conditions for p53 protein detection. The parameters for p53 dysfunction were correlated to DNA aneuploidy measured by flow cytometry. TP53 mutations were significantly associated with DNA aneuploidy (P <0.00001), and a nonrandom distribution of TP53 gene alterations among diploid (DI = 1), hyperdiploid (1.0 < DI < 1.3), and highly aneuploid (DI > 1.3) tumors indicates that DNA hyperdiploid tumors constitute a separate developmental entity different from tumors with gross aneuploidy. (C) Lippincott-Raven Publishers.